Trial Outcomes & Findings for Clinical Trial of a Supporter-Targeted Intervention to Improve Outcomes in Recent Sexual Assault Survivors (NCT NCT05345405)

NCT ID: NCT05345405

Last Updated: 2025-06-08

Results Overview

Sum score on Client Satisfaction Scale, completed by survivor. Range: 8 to 32; higher scores indicate greater satisfaction

• Recruitment status: COMPLETED
• Study phase: NA
• Target enrollment: 128 participants
• Primary outcome timeframe: 1 month
• Results posted on: 2025-06-08

Participant Flow

Participant milestones

Measure	Dyadic CARE Dyads randomized to receive dyadic CARE. Dyadic CARE involved both dyad members attending 2 sessions and completing a workbook together. Session 1 typically occurred immediately following baseline/randomization (maximum: 2 weeks later). Session 2 typically occurred 2 weeks after Session 1 (maximum: 4 weeks later).	Supporter-Only CARE Dyads randomized to receive supporter-only CARE. Supporter-only CARE involved the supporter attending 2 sessions and completing a workbook with the survivor. Session 1 typically occurred immediately following baseline/randomization (maximum: 2 weeks later). Session 2 typically occurred 2 weeks after Session 1 (maximum: 4 weeks later).	Waitlist Control Dyads randomized to receive waitlist CARE (invited to complete the CARE version of the survivor's choice following the completion of study measures)
Overall Study STARTED	42	44	42
Overall Study COMPLETED	40	42	41
Overall Study NOT COMPLETED	2	2	1

Reasons for withdrawal

Measure	Dyadic CARE Dyads randomized to receive dyadic CARE. Dyadic CARE involved both dyad members attending 2 sessions and completing a workbook together. Session 1 typically occurred immediately following baseline/randomization (maximum: 2 weeks later). Session 2 typically occurred 2 weeks after Session 1 (maximum: 4 weeks later).	Supporter-Only CARE Dyads randomized to receive supporter-only CARE. Supporter-only CARE involved the supporter attending 2 sessions and completing a workbook with the survivor. Session 1 typically occurred immediately following baseline/randomization (maximum: 2 weeks later). Session 2 typically occurred 2 weeks after Session 1 (maximum: 4 weeks later).	Waitlist Control Dyads randomized to receive waitlist CARE (invited to complete the CARE version of the survivor's choice following the completion of study measures)
Overall Study Withdrawal by Subject	2	0	0
Overall Study Did not meet eligibility criteria	0	2	0
Overall Study Lost to Follow-up	0	0	1

Baseline Characteristics

One participant did not report their age. Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.

Baseline characteristics by cohort

Measure	Dyadic CARE (Survivors) n=21 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=22 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)	Dyadic CARE (Supporters) n=21 Participants Supporters randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Supporters) n=22 Participants Supporters randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Supporters) n=21 Participants Supporters randomized to receive waitlist CARE (invited to complete the CARE version of the survivor's choice following the completion of study measures)	Total n=128 Participants Total of all reporting groups
Age, Continuous	26.48 Years STANDARD_DEVIATION 9.56 • n=21 Participants • One participant did not report their age. Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	23.24 Years STANDARD_DEVIATION 6.07 • n=21 Participants • One participant did not report their age. Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	25.52 Years STANDARD_DEVIATION 9.32 • n=21 Participants • One participant did not report their age. Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	32.48 Years STANDARD_DEVIATION 10.75 • n=21 Participants • One participant did not report their age. Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	37.52 Years STANDARD_DEVIATION 15.38 • n=21 Participants • One participant did not report their age. Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	30.80 Years STANDARD_DEVIATION 11.87 • n=20 Participants • One participant did not report their age. Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	29.33 Years STANDARD_DEVIATION 11.69 • n=125 Participants • One participant did not report their age. Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.
Sex: Female, Male Female	19 Participants n=20 Participants • One participant did not report sex. Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	18 Participants n=21 Participants • One participant did not report sex. Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	20 Participants n=21 Participants • One participant did not report sex. Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	13 Participants n=21 Participants • One participant did not report sex. Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	16 Participants n=21 Participants • One participant did not report sex. Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	16 Participants n=21 Participants • One participant did not report sex. Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	102 Participants n=125 Participants • One participant did not report sex. Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.
Sex: Female, Male Male	1 Participants n=20 Participants • One participant did not report sex. Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	3 Participants n=21 Participants • One participant did not report sex. Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	1 Participants n=21 Participants • One participant did not report sex. Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	8 Participants n=21 Participants • One participant did not report sex. Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	5 Participants n=21 Participants • One participant did not report sex. Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	5 Participants n=21 Participants • One participant did not report sex. Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	23 Participants n=125 Participants • One participant did not report sex. Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.
Ethnicity (NIH/OMB) Hispanic or Latino	4 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	5 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	4 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	17 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	18 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	18 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	66 Participants n=126 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.
Ethnicity (NIH/OMB) Not Hispanic or Latino	17 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	16 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	17 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	4 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	3 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	3 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	60 Participants n=126 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	0 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	0 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	0 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	0 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	0 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	0 Participants n=126 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	1 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	0 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	0 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	0 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	0 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	1 Participants n=126 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.
Race (NIH/OMB) Asian	5 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	6 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	4 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	5 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	6 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	4 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	30 Participants n=126 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	0 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	0 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	0 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	0 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	0 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	0 Participants n=126 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.
Race (NIH/OMB) Black or African American	1 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	0 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	0 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	2 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	0 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	1 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	4 Participants n=126 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.
Race (NIH/OMB) White	7 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	8 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	12 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	9 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	10 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	13 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	59 Participants n=126 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.
Race (NIH/OMB) More than one race	5 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	3 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	3 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	2 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	1 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	0 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	14 Participants n=126 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.
Race (NIH/OMB) Unknown or Not Reported	3 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	3 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	2 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	3 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	4 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	3 Participants n=21 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.	18 Participants n=126 Participants • Two participants were withdrawn by researchers for not meeting eligibility and were not included in analyses.

PRIMARY outcome

Timeframe: 1 month

Population: 2 participants did not complete this scale.

Sum score on Client Satisfaction Scale, completed by survivor. Range: 8 to 32; higher scores indicate greater satisfaction

Outcome measures

Measure	Dyadic CARE (Survivors) n=19 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=21 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Survivor Satisfaction With Intervention at 1 Month Post-baseline (Self Report)	28.37 score on a scale Standard Deviation 3.39	27.71 score on a scale Standard Deviation 3.51	—

PRIMARY outcome

Timeframe: 1 month

Population: 2 participants did not complete this scale.

Sum score on Client Satisfaction Scale, completed by supporter. Range: 8 to 32; higher scores indicate greater satisfaction

Outcome measures

Measure	Dyadic CARE (Survivors) n=20 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=20 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Supporter Satisfaction With Intervention at 1 Month Post-baseline (Self Report)	29.79 score on a scale Standard Deviation 2.65	29.60 score on a scale Standard Deviation 2.28	—

PRIMARY outcome

Timeframe: Baseline, 1 month

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Sum score on a knowledge questionnaire reflecting CARE concepts, completed by the survivor. Range: 8 to 40; higher scores indicate more knowledge about CARE concepts.

Outcome measures

Measure	Dyadic CARE (Survivors) n=17 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=20 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=20 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Survivor Knowledge at 1 Month Post-baseline (Self Report)	3.24 score on a scale Standard Deviation 3.70	0.20 score on a scale Standard Deviation 3.47	0.61 score on a scale Standard Deviation 4.75

PRIMARY outcome

Timeframe: Baseline, 1 month

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Sum score on a knowledge questionnaire reflecting CARE concepts, completed by the supporter. Range: 9 to 45; higher scores indicate more knowledge about CARE concepts.

Outcome measures

Measure	Dyadic CARE (Survivors) n=18 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=19 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=18 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Supporter Knowledge at 1 Month Post-baseline (Self Report)	4.61 Points Standard Deviation 2.93	4.84 Points Standard Deviation 3.55	0.33 Points Standard Deviation 2.54

PRIMARY outcome

Timeframe: Baseline, 1 month

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Sum score on 4-item measure created for this study, completed by survivor. Range: 4 to 20; higher scores indicate greater confusion.

Outcome measures

Measure	Dyadic CARE (Survivors) n=19 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=21 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Survivor Confusion About Help-seeking Behavior at 1 Month Post-baseline (Self Report)	-2.21 score on a scale Standard Deviation 4.04	-1.14 score on a scale Standard Deviation 3.64	0.86 score on a scale Standard Deviation 4.50

PRIMARY outcome

Timeframe: Baseline, 1 month

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Sum score on the Confusion subscale of the Impact on Friends scale, completed by supporter. Range: 6 to 30; higher scores indicate greater confusion about helping behavior.

Outcome measures

Measure	Dyadic CARE (Survivors) n=20 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=20 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=20 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Supporter Confusion About Helping Behavior at 1 Month Post-baseline (Self Report)	-4.35 score on a scale Standard Deviation 3.88	-3.70 score on a scale Standard Deviation 3.42	-1.85 score on a scale Standard Deviation 3.23

PRIMARY outcome

Timeframe: 1 month

Population: Participants were excluded if they did not complete this scale.

Single item representing frequency of disclosures to supporter in past month, completed by survivor, adapted from the Early Intervention Clinic Disclosure scale. Survivor will input a numerical response representing number of disclosures. Higher scores indicate more frequent disclosure.

Outcome measures

Measure	Dyadic CARE (Survivors) n=21 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=21 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Survivor Disclosure Frequency to Supporter at 1 Month Post-baseline (Self Report)	2.67 number of disclosures Standard Error 0.21	3.02 number of disclosures Standard Error 0.21	2.66 number of disclosures Standard Error 0.21

PRIMARY outcome

Timeframe: 1 month

Population: Only assessed among survivors reporting past-month disclosure to the supporter

Sum score on Turning Against subscale of the Social Reactions Questionnaire - Shortened, completed by survivor in reference to supporter's reactions in past month. Range: 0 to 24; higher scores indicate more frequent hostile negative reactions.

Outcome measures

Measure	Dyadic CARE (Survivors) n=15 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=18 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=17 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Supporter Overt Hostile Reactions to Disclosure at 1 Month Post-baseline (Informant Report)	1.41 score on a scale Standard Error 0.53	2.96 score on a scale Standard Error 0.49	2.49 score on a scale Standard Error 0.50

PRIMARY outcome

Timeframe: 1 month

Population: Only assessed among survivors reporting past-month disclosure to the supporter

Sum score on Unsupportive Acknowledgment subscale of the Social Reactions Questionnaire - Shortened, completed by survivor in reference to supporter's reactions in past month. Range: 0 to 24; higher scores indicate more frequent subtly unsupportive reactions.

Outcome measures

Measure	Dyadic CARE (Survivors) n=15 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=18 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=17 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Supporter Subtly Unsupportive Reactions to Disclosure at 1 Month Post-baseline (Informant Report)	2.04 score on a scale Standard Error 0.57	2.23 score on a scale Standard Error 0.52	3.34 score on a scale Standard Error 0.54

PRIMARY outcome

Timeframe: Baseline & 1 month

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Sum score on the Responsiveness subscale of the Perceived Responsiveness and Insensitivity scale, completed by survivor in reference to past month. Range: 0 to 40; higher scores indicate greater responsiveness.

Outcome measures

Measure	Dyadic CARE (Survivors) n=19 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=21 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Supporter Responsiveness at 1 Month Post-baseline (Informant Report)	-2.21 score on a scale Standard Deviation 5.90	-0.10 score on a scale Standard Deviation 7.49	0.14 score on a scale Standard Deviation 8.24

PRIMARY outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Sum score on PTSD Checklist-5 (PCL-5), completed by survivor in reference to past month. Range: 0-80; higher scores indicate greater severity of PTSD symptoms.

Outcome measures

Measure	Dyadic CARE (Survivors) n=17 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=19 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Survivor PTSD Symptom Severity at 3 Months Post-baseline (Self Report)	-12.12 score on a scale Standard Deviation 17.54	-16.58 score on a scale Standard Deviation 13.32	-16.25 score on a scale Standard Deviation 13.32

PRIMARY outcome

Timeframe: 3 months

Population: Participants were excluded if they did not complete the scale at 3 months post baseline

Provisional PTSD diagnostic status based on PTSD Checklist-5 (PCL-5), completed by survivor in reference to past month. Survivors will be considered to have a provisional diagnosis if the following items are rated as 2 = "Moderately" or higher: one Criterion B item (questions 1-5), one Criterion C item (questions 6-7), two Criterion D items (questions 8-14), and two Criterion E items (questions 15-20).

Outcome measures

Measure	Dyadic CARE (Survivors) n=17 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=19 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Survivor Provisional PTSD Diagnostic Status at 3 Months Post-baseline (Self Report)	8 Participants	5 Participants	9 Participants

PRIMARY outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Sum score on the Stress subscale of the Depression and Anxiety Stress Scales (DASS-21), completed by survivor in reference to past week. Range: 0 to 21; higher scores indicate greater stress.

Outcome measures

Measure	Dyadic CARE (Survivors) n=19 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=20 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Survivor Stress at 3 Months Post-baseline (Self Report)	-1.66 score on a scale Standard Deviation 5.39	-2.42 score on a scale Standard Deviation 3.56	-1.38 score on a scale Standard Deviation 3.58

PRIMARY outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Sum score on the Stress subscale of the Depression and Anxiety Stress Scales (DASS-21), completed by supporter in reference to past week. Range: 0 to 21; higher scores indicate greater stress.

Outcome measures

Measure	Dyadic CARE (Survivors) n=20 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=18 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=20 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Supporter Stress at 3 Months Post-baseline (Self Report)	-2.15 score on a scale Standard Deviation 3.30	-1.22 score on a scale Standard Deviation 3.32	-0.65 score on a scale Standard Deviation 3.07

PRIMARY outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Sum score on the Relationship Assessment Scale, completed by survivor. Range: 7 to 35; higher scores indicate greater relationship quality.

Outcome measures

Measure	Dyadic CARE (Survivors) n=19 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=20 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Survivor Perceived Relationship Quality at 3 Months Post-baseline (Self Report)	-0.39 score on a scale Standard Deviation 2.50	-1.60 score on a scale Standard Deviation 4.45	-1.76 score on a scale Standard Deviation 4.12

PRIMARY outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Sum score on the Relationship Assessment Scale, completed by supporter. Range: 7 to 35; higher scores indicate greater relationship quality.

Outcome measures

Measure	Dyadic CARE (Survivors) n=20 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=18 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=20 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Supporter Perceived Relationship Quality at 3 Months Post-baseline (Self Report)	0.35 score on a scale Standard Deviation 3.94	0.39 score on a scale Standard Deviation 2.00	-2.10 score on a scale Standard Deviation 4.33

SECONDARY outcome

Timeframe: 1 month

Population: Participants were excluded if they did not complete this scale.

Sum score score on measure created for this study, completed by survivor. Range: 0 to 10; higher scores indicate greater willingness.

Outcome measures

Measure	Dyadic CARE (Survivors) n=19 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=21 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Survivor Willingness to Participate in Criminal Justice Process at 1 Month Post-baseline (Self Report)	-0.21 score on a scale Standard Deviation 1.69	0.57 score on a scale Standard Deviation 1.99	-0.19 score on a scale Standard Deviation 1.33

SECONDARY outcome

Timeframe: 1 month

Population: Participants were excluded if they did not complete this scale.

Mean score on measure created for this study, completed by survivor. Range: 0 to 1; higher scores indicate greater participation.

Outcome measures

Measure	Dyadic CARE (Survivors) n=21 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=21 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Survivor Participation in Criminal Justice Process at 1 Month Post-baseline (Self Report)	0.64 score on a scale Standard Error 0.07	0.49 score on a scale Standard Error 0.07	0.52 score on a scale Standard Error 0.07

SECONDARY outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Sum score on the Depression subscale of the Depression and Anxiety Stress Scales (DASS-21), completed by survivor in reference to past week. Range: 0 to 21; higher scores indicate greater depression.

Outcome measures

Measure	Dyadic CARE (Survivors) n=19 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=20 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Survivor Depression at 3 Months Post-baseline (Self Report)	-1.58 score on a scale Standard Deviation 6.15	-3.00 score on a scale Standard Deviation 3.15	-2.52 score on a scale Standard Deviation 4.57

SECONDARY outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Sum score on the Depression subscale of the Depression and Anxiety Stress Scales (DASS-21), completed by supporter in reference to past week. Range: 0 to 21; higher scores indicate greater depression.

Outcome measures

Measure	Dyadic CARE (Survivors) n=20 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=18 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=20 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Supporter Depression at 3 Months Post-baseline (Self Report)	-0.80 score on a scale Standard Deviation 2.88	-0.72 score on a scale Standard Deviation 2.02	0.44 score on a scale Standard Deviation 4.05

SECONDARY outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Sum score on the Anxiety subscale of the Depression and Anxiety Stress Scales (DASS-21), completed by survivor in reference to past week. Range: 0 to 21; higher scores indicate greater anxiety.

Outcome measures

Measure	Dyadic CARE (Survivors) n=19 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=20 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Survivor Anxiety at 3 Months Post-baseline (Self Report)	-1.53 score on a scale Standard Deviation 4.50	-1.50 score on a scale Standard Deviation 3.22	-2.10 score on a scale Standard Deviation 5.40

SECONDARY outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Sum score on the Anxiety subscale of the Depression and Anxiety Stress Scales (DASS-21), completed by supporter in reference to past week. Range: 0 to 21; higher scores indicate greater anxiety.

Outcome measures

Measure	Dyadic CARE (Survivors) n=21 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=21 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Supporter Anxiety at 3 Months Post-baseline (Self Report)	0.33 score on a scale Standard Deviation 1.53	1.00 score on a scale Standard Deviation 2.51	0.33 score on a scale Standard Deviation 1.53

SECONDARY outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Sum score on Work/School/Responsibility Impairment subscale of the Behavioral Activation for Depression Scale (BADS), completed by survivor in reference to past week. Range: 0 to 30; higher scores indicate more impairment.

Outcome measures

Measure	Dyadic CARE (Survivors) n=19 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=20 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Survivor Role Impairment at 3 Months Post-baseline (Self Report)	-2.95 score on a scale Standard Deviation 6.97	-3.75 score on a scale Standard Deviation 5.82	-4.00 score on a scale Standard Deviation 5.02

SECONDARY outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Sum score on Social Impairment subscale of the Behavioral Activation for Depression Scale (BADS), completed by survivor in reference to past week. Range: 0 to 30; higher scores indicate more impairment.

Outcome measures

Measure	Dyadic CARE (Survivors) n=19 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=20 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Survivor Social Impairment at 3 Months Post-baseline (Self Report)	-3.21 score on a scale Standard Deviation 6.60	-0.40 score on a scale Standard Deviation 7.71	-1.57 score on a scale Standard Deviation 7.72

SECONDARY outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Sum score on Flourishing Index Measure, completed by survivor. Range: 0 to 120; higher scores indicate more flourishing.

Outcome measures

Measure	Dyadic CARE (Survivors) n=19 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=19 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Survivor Flourishing at 3 Months Post-baseline (Self Report)	0.21 score on a scale Standard Deviation 16.70	2.89 score on a scale Standard Deviation 12.43	-2.90 score on a scale Standard Deviation 13.43

SECONDARY outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Sum score on Flourishing Index Measure, completed by supporter. Range: 0 to 120; higher scores indicate more flourishing.

Outcome measures

Measure	Dyadic CARE (Survivors) n=20 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=20 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=20 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Supporter Flourishing at 3 Months Post-baseline (Self Report)	1.65 score on a scale Standard Deviation 10.39	5.22 score on a scale Standard Deviation 9.52	-7.33 score on a scale Standard Deviation 17.39

SECONDARY outcome

Timeframe: 1 month

Population: Participants were excluded if they did not complete this scale.

Mean score on ratings of distress associated endorsed items on Negative Reactions subscale of the Social Reactions Questionnaire - Shortened, completed by survivor in reference to supporter's reactions to survivor in past month. Range: 0 to 3; higher scores indicate more distress.

Outcome measures

Measure	Dyadic CARE (Survivors) n=21 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=21 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Survivor Distress Associated With Supporter Negative Reactions at 1 Month Post-baseline (Self Report)	1.28 score on a scale Standard Error 0.28	1.50 score on a scale Standard Error 0.24	1.37 score on a scale Standard Error 0.23

SECONDARY outcome

Timeframe: 1 month

Population: Only assessed among survivors reporting past-month disclosure to the supporter

Sum score on Positive Reactions subscale of the Social Reactions Questionnaire - Shortened, completed by survivor in reference to supporter's reactions in past month. Range: 0 to 16; higher scores indicate more frequent positive reactions.

Outcome measures

Measure	Dyadic CARE (Survivors) n=15 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=19 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=16 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Supporter Positive Reactions to Disclosure at 1 Month Post-baseline (Informant Report)	8.56 score on a scale Standard Error 1.02	9.53 score on a scale Standard Error 0.85	8.56 score on a scale Standard Error 1.02

SECONDARY outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Number of typical drinks per week in past month reported by survivor on the Daily Drinking Questionnaire

Outcome measures

Measure	Dyadic CARE (Survivors) n=19 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=20 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=20 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Survivor Typical Alcohol Consumption (Quantity) at 3 Months Post-baseline (Self Report)	0.58 drinks per week Standard Deviation 5.96	-1.80 drinks per week Standard Deviation 2.89	-0.25 drinks per week Standard Deviation 9.30

SECONDARY outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Number of typical drinking days per week in past month reported by survivor on the Daily Drinking Questionnaire. Range: 0 to 7.

Outcome measures

Measure	Dyadic CARE (Survivors) n=19 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=20 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=20 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Survivor Typical Alcohol Consumption (Frequency) at 3 Months Post-baseline (Self Report)	0.32 days per week Standard Deviation 1.60	-0.40 days per week Standard Deviation 0.99	0.25 days per week Standard Deviation 1.65

SECONDARY outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Number of typical drinking hours per week in past month reported by survivor on the Daily Drinking Questionnaire.

Outcome measures

Measure	Dyadic CARE (Survivors) n=19 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=19 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=20 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Survivor Typical Alcohol Consumption (Hours) at 3 Months Post-baseline (Self Report)	1.32 hours per week Standard Deviation 7.45	-0.79 hours per week Standard Deviation 3.87	-1.95 hours per week Standard Deviation 8.51

SECONDARY outcome

Timeframe: 1 month

Population: Participants were excluded if they did not complete this scale.

Sum score on the Confusion subscale of the Impact on Friends measure, completed by supporter in reference to the past month. Range: 6 to 30; higher scores indicate greater perceived ineffectiveness.

Outcome measures

Measure	Dyadic CARE (Survivors) n=21 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=21 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Supporter Perceived Helping Ineffectiveness at 1 Month Post-baseline (Self Report)	12.13 score on a scale Standard Error 0.91	12.78 score on a scale Standard Error 0.90	14.57 score on a scale Standard Error 0.91

SECONDARY outcome

Timeframe: 1 month

Population: Participants were excluded if they did not complete this scale.

Sum score on the Emotional Distress subscale of the Impact on Friends measure, completed by supporter in reference to the past month. Range: 24 to 120; higher scores indicate greater distress.

Outcome measures

Measure	Dyadic CARE (Survivors) n=21 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=21 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Supporter Distress in Helping at 1 Month Post-baseline (Self Report)	53.59 score on a scale Standard Error 2.82	55.99 score on a scale Standard Error 2.80	61.57 score on a scale Standard Error 2.83

SECONDARY outcome

Timeframe: 1 month

Population: Participants were excluded if they did not complete this scale.

Sum score on the Significant Others' Responses to Trauma Scale (SORTS), completed by supporter in reference to the past month. Range: 0 to 112; higher scores indicate greater accommodation.

Outcome measures

Measure	Dyadic CARE (Survivors) n=20 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=20 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=20 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Supporter Accommodation of Survivor PTSD Symptoms at 1 Month Post-baseline (Self Report)	12.78 score on a scale Standard Error 2.96	8.64 score on a scale Standard Error 2.95	17.66 score on a scale Standard Error 2.01

SECONDARY outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Number of days of cannabis use in past 2 weeks, as reported by survivor. Range: 0 to 14.

Outcome measures

Measure	Dyadic CARE (Survivors) n=19 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=19 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Survivor Cannabis Use Frequency at 3 Months Post-baseline (Self Report)	-0.11 Days Standard Deviation 1.79	0.63 Days Standard Deviation 2.39	-1.62 Days Standard Deviation 2.91

SECONDARY outcome

Timeframe: Baseline, 3 months

Population: Analyses could not be performed because no participants reported opioid use.

Number of days of prescription opioid use not as prescribed in past 2 weeks, as reported by survivor. Range: 0 to 14.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline, 3 months

Population: Analyses could not be performed because no participants reported non-prescription opioid use.

Number of days of non-prescription opioid use in past 2 weeks, as reported by survivor. Range: 0 to 14.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Number of days of prescription amphetamine use not as prescribed in past 2 weeks, as reported by survivor. Range: 0 to 14.

Outcome measures

Measure	Dyadic CARE (Survivors) n=19 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=19 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Survivor Prescription Amphetamine Misuse Frequency at 3 Months Post-baseline (Self Report)	0.11 Days Standard Deviation 0.46	-0.05 Days Standard Deviation 0.23	0.24 Days Standard Deviation 1.09

SECONDARY outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Number of days of methamphetamine use in past 2 weeks, as reported by survivor. Range: 0 to 14.

Outcome measures

Measure	Dyadic CARE (Survivors) n=19 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=21 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Survivor Methamphetamine Use Frequency at 3 Months Post-baseline (Self Report)	0.16 Days Standard Deviation 0.69	0.29 Days Standard Deviation 1.31	-0.19 Days Standard Deviation 0.87

SECONDARY outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Number of days of cigarette use in past 2 weeks, as reported by survivor. Range: 0 to 14.

Outcome measures

Measure	Dyadic CARE (Survivors) n=19 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=19 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Survivor Cigarette Use Frequency at 3 Months Post-baseline (Self Report)	-0.05 Days Standard Deviation 0.23	-0.16 Days Standard Deviation 0.37	-0.10 Days Standard Deviation 0.44

SECONDARY outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Number of cigarettes smoked in a typical day in past 2 weeks, as reported by survivor.

Outcome measures

Measure	Dyadic CARE (Survivors) n=19 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=20 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Survivor Cigarette Use Quantity at 3 Months Post-baseline (Self Report)	-0.01 Cigarettes Per Day Standard Deviation 0.05	-1.05 Cigarettes Per Day Standard Deviation 3.36	-0.62 Cigarettes Per Day Standard Deviation 2.62

OTHER_PRE_SPECIFIED outcome

Timeframe: 1 month

Population: Participants were excluded if they did not complete this item.

Single item representing frequency of survivor's disclosures to supporter in past month, completed by supporter, adapted from the Early Intervention Clinic Disclosure Scale. Participants were instructed to enter a numerical value corresponding to number of disclosures. Higher scores indicate more frequent disclosure.

Outcome measures

Measure	Dyadic CARE (Survivors) n=21 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=21 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=21 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Survivor Disclosure Frequency to Supporter at 1 Month Post-baseline (Informant Report)	2.56 disclosures Standard Error 0.21	2.70 disclosures Standard Error 0.21	2.02 disclosures Standard Error 0.20

OTHER_PRE_SPECIFIED outcome

Timeframe: 1 month

Population: Only assessed among supporters reporting past-month receipt of disclosure from the survivor

Sum score on Negative Reactions subscale of the Social Reactions Questionnaire - Shortened, completed by supporter in reference to supporter's reactions to survivor in past month. Range: 0 to 48; higher scores indicate more frequent negative reactions.

Outcome measures

Measure	Dyadic CARE (Survivors) n=18 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=19 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=11 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Supporter Negative Reactions to Disclosure at 1 Month Post-baseline (Self Report)	2.22 score on a scale Standard Deviation 3.12	1.79 score on a scale Standard Deviation 2.20	4.19 score on a scale Standard Deviation 3.62

OTHER_PRE_SPECIFIED outcome

Timeframe: 1 month

Population: Only assessed among supporters reporting past-month receipt of disclosure from the survivor

Sum score on Positive Reactions subscale of the Social Reactions Questionnaire - Shortened, completed by supporter in reference to supporter's reactions to survivor in past month. Range: 0 to 16; higher scores indicate more frequent positive reactions.

Outcome measures

Measure	Dyadic CARE (Survivors) n=18 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=19 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=11 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Supporter Positive Reactions to Disclosure at 1 Month Post-baseline (Self Report)	8.56 score on a scale Standard Error 0.63	8.74 score on a scale Standard Error 0.69	9.36 score on a scale Standard Error 0.99

OTHER_PRE_SPECIFIED outcome

Timeframe: 1 month

Population: Participants were excluded if they did not complete this scale.

Sum score on survey created for this study, completed by survivor. Range: 4 to 16; higher scores indicate greater perceived cultural responsiveness of intervention.

Outcome measures

Measure	Dyadic CARE (Survivors) n=19 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=21 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Survivor Perceived Cultural Responsiveness of Intervention at 1 Month Post-baseline (Self Report)	9.84 score on a scale Standard Deviation 1.74	10.19 score on a scale Standard Deviation 1.99	—

OTHER_PRE_SPECIFIED outcome

Timeframe: 1 month

Population: Participants were excluded if they did not complete this scale.

Sum score on survey created for this study, completed by survivor. Range: 4 to 16; higher scores indicate greater perceived cultural responsiveness of intervention.

Outcome measures

Measure	Dyadic CARE (Survivors) n=20 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=20 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Supporter Perceived Cultural Responsiveness of Intervention at 1 Month Post-baseline (Self Report)	10.35 score on a scale Standard Deviation 1.84	10.45 score on a scale Standard Deviation 1.76	—

OTHER_PRE_SPECIFIED outcome

Timeframe: 1 month

Population: Participants were excluded if they did not complete this scale.

Sum score on survey created for this study, completed by survivor. Range: 4 to 20; higher scores indicate greater perceived impact of intervention.

Outcome measures

Measure	Dyadic CARE (Survivors) n=18 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=21 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Survivor Perceived Impact of Intervention at 1 Month Post-baseline (Self-report)	16.56 score on a scale Standard Deviation 2.50	15.71 score on a scale Standard Deviation 2.37	—

OTHER_PRE_SPECIFIED outcome

Timeframe: 1 month

Population: Participants were excluded if they did not complete this scale.

Sum score on survey created for this study, completed by supporter. Range: 4 to 20; higher scores indicate greater perceived impact of intervention.

Outcome measures

Measure	Dyadic CARE (Survivors) n=20 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=20 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Supporter Perceived Impact of Intervention at 1 Month Post-baseline (Self-report)	16.80 score on a scale Standard Deviation 2.53	16.60 score on a scale Standard Deviation 2.19	—

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Number of typical drinks per week in past month reported by supporter on the Daily Drinking Questionnaire. Range: 0 to 7.

Outcome measures

Measure	Dyadic CARE (Survivors) n=20 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=18 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=19 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Supporter Typical Alcohol Consumption (Quantity) at 3 Months Post-baseline (Self Report)	0.25 Drinks Per Week Standard Deviation 2.59	-0.78 Drinks Per Week Standard Deviation 1.48	-1.87 Drinks Per Week Standard Deviation 5.99

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Number of typical drinking days per week in past month reported by supporter on the Daily Drinking Questionnaire. Range: 0 to 7.

Outcome measures

Measure	Dyadic CARE (Survivors) n=20 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=18 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=19 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Supporter Typical Alcohol Consumption (Frequency) at 3 Months Post-baseline (Self Report)	0.05 Days Per Week Standard Deviation 0.83	-0.22 Days Per Week Standard Deviation 0.69	-0.21 Days Per Week Standard Deviation 1.32

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Number of typical drinking hours per week in past month reported by supporter on the Daily Drinking Questionnaire.

Outcome measures

Measure	Dyadic CARE (Survivors) n=20 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=18 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=19 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Supporter Typical Alcohol Consumption (Hours) at 3 Months Post-baseline (Self Report)	2.30 Hours Per Week Standard Deviation 8.90	-0.89 Hours Per Week Standard Deviation 2.03	-1.26 Hours Per Week Standard Deviation 7.09

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments.

Number of days of cannabis use in past 2 weeks, as reported by supporter. Range: 0 to 14.

Outcome measures

Measure	Dyadic CARE (Survivors) n=20 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) n=18 Participants Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=20 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Supporter Cannabis Use Frequency at 3 Months Post-baseline (Self Report)	0.45 Days Standard Deviation 1.88	-0.11 Days Standard Deviation 0.32	-0.85 Days Standard Deviation 3.56

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline, 3 months

Population: It was not possible to compute change scores because no participants reported prescription opioid use at any assessment

Number of days of prescription opioid use not as prescribed in past 2 weeks, as reported by supporter. Range: 0 to 14.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline, 3 months

Population: It was not possible to compute change scores because no participants reported non-prescription opioid use at any assessment

Number of days of non-prescription opioid use in past 2 weeks, as reported by supporter. Range: 0 to 14.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline, 3 months

Population: It was not possible to compute change scores because amphetamine use was very low base rate

Number of days of prescription amphetamine use not as prescribed in past 2 weeks, as reported by supporter. Range: 0 to 14.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline, 3 months

Population: It was not possible to compute change scores because no participants reported methamphetamine use at any assessment

Number of days of methamphetamine use in past 2 weeks, as reported by supporter. Range: 0 to 14.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments. It was not possible to compute change scores for the Supporter-only condition because no participants reported cigarette use.

Number of days of cigarette use in past 2 weeks, as reported by supporter. Range: 0 to 14.

Outcome measures

Measure	Dyadic CARE (Survivors) n=20 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=20 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Supporter Cigarette Use Frequency at 3 Months Post-baseline (Self Report)	-0.10 Days Standard Deviation 0.31	—	-0.15 Days Standard Deviation 2.37

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline, 3 months

Population: Because this is a change score, participants were excluded listwise if they had missing data at one or both assessments. It was not possible to compute change scores for the Supporter-only condition because no participants reported cigarette use.

Number of cigarettes smoked in a typical day in past 2 weeks, as reported by supporter.

Outcome measures

Measure	Dyadic CARE (Survivors) n=20 Participants Survivors randomized to receive dyadic CARE (both dyad members attended both sessions and completed a workbook together)	Supporter-Only CARE (Survivors) Survivors randomized to receive supporter-only CARE (only the supporter attended both sessions; the dyad completed a workbook together)	Waitlist Control (Survivors) n=20 Participants Survivors randomized to receive waitlist CARE (invited to complete the CARE version of their choice following the completion of study measures)
Change in Supporter Cigarette Use Quantity at 3 Months Post-baseline (Self Report)	-0.05 Cigarettes Per Day Standard Deviation 0.22	—	-0.18 Cigarettes Per Day Standard Deviation 1.16

Adverse Events

Dyadic CARE (Survivors)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Supporter-Only CARE (Survivors)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Waitlist Control (Survivors)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Dyadic CARE (Supporters)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Supporter-Only CARE (Supporters)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Waitlist Control (Supporters)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Principal Investigator

University of Washington

Phone: 206-503-3287

Email: edworkin@uw.edu

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place